Quantoom Biosciences and TechInvention Lifecare have entered into a strategic collaboration to accelerate the development and manufacture of RNA-based therapeutics in India.
The Memorandum of Understanding, which was signed during Belgium's economic mission to India, will bring Quantoom's RNA N-Force toolbox to India — which aims to enhance the accessibility, scalability and affordability of RNA therapeutics in the region.
Quantoom's toolbox will assist in the development of m(sa)RNA-based vaccines at each step through sequence design, naked RNA production and encapsulation.
TechInvention will utilise these tools to steamline the development, scale-up and commercialisation process of RNA-based products, with the company planning to be EU GMP-ready by the end of 2025.
The collaboration will also aim to improve the environmental sustainability of RNA manufacturing in the region.
"Partnering with TechInvention in India is a vital step towards making RNA products accessible and scalable globally," noted CEO of Quantoom, José Castillo.
"Thanks to our end-to-end N-Force Toolbox, we can ensure that citizens in the most populated country in the world can gain access to RNA-based therapeutics that can save lives," he said.
Syed Ahmed, Director & CEO, TechInvention, commented: "Our partnership with Quantoom is a significant step toward strenghtening India's preparedness for future pandemics, while ensuring broader access to RNA-based innovations throughout the country," added Director and CEO of TechInvention, Syed Ahmed.
This collaboration positions India as a hub for next-gen RNA-based vaccines, driving global partnerships for equitable healthcare.
